CLOV Clover Health Investments, Corp. - Class A Common stock

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Central banks are talking about higher interest rates for longer, and the OECD expects global inflation to linger. Cash in a savings account may feel safer, but it can struggle to keep up with rising prices. That is why some investors are looking at lower priced, financially robust smaller stocks as a way to stay in the game. This article highlights 3 such penny stocks for investors to examine more closely. The three penny stocks in this article are only a small sample, and the full screen...

Clover Health Investments (NASDAQ:CLOV) is positioning its Medicare Advantage business to benefit from industry pricing discipline, member retention and the maturation of member cohorts, Interim Chief Financial Officer Clay Thornton said at Jefferies’ Healthcare Services and Technology Conference in

A number of stocks fell in the morning session after bipartisan lawmakers introduced the Protecting Approved Care Act, legislation aimed at reforming prior authorization and payment rules in Medicare Advantage plans.

The Medicare Advantage insurer had already faced skepticism after its second-quarter report. Tuesday’s comments reinforced that picture.

Clover Health Investments (NASDAQ:CLOV) grew its share price by 8.53 percent on Thursday to finish at $4.71 apiece, as investors took heart from Deutsche Bank’s optimistic rating for its stock. In its initial coverage of the stock, the investment firm assigned a buy recommendation on shares of Clover Health Investments (NASDAQ:CLOV) alongside a price target […]

Shares of health insurance company Clover Health (NASDAQ:CLOV) jumped 8.5% in the afternoon session after Deutsche Bank initiated coverage on the company with a Buy rating and a $6.00 price target.

Global services sectors are still growing, and employment is holding up in many major economies, even as costs remain a concern. That mix of resilience and pressure keeps investors hunting for lower priced stocks that still have enough cash to fund their plans. This article highlights three cash backed penny stocks from our premium low price screener that aim to give you early stage exposure with fewer balance sheet red flags. The stocks in the list below are just a starting sample, and the...

On August 5, Clover Health Investments Corp. (NASDAQ:CLOV) reported second-quarter 2026 results that turned a year-ago loss into real profit. GAAP net income came in at $28 million, a $39 million swing from the $10.6 million loss posted in the same quarter last year. Medicare Advantage membership climbed to 157,309, up 48% year over year, […]

Germany’s 10 year bond yield is near levels last seen in 2011, which shows how firmly markets are pricing in higher-for-longer interest rates. Higher yields often pressure richly valued large caps. That shifts more attention toward Financially Fit Penny Stocks, where entry prices are lower and balance sheets play a larger role. This article highlights three stocks from the screener that combine penny stock pricing with a focus on financial health. The three Financially Fit Penny Stocks in...

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 28.9% gain over the past six months, beating the S&P 500 by 18 percentage points.

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.

Let’s dig into the relative performance of Clover Health (NASDAQ:CLOV) and its peers as we unravel the now-completed Q2 health insurance providers earnings season.

Clover Health Investments has delivered a very strong 227.7% return over the past 3 years, yet the share price around US$4.49 now lines up with valuation checks that suggest the stock no longer looks obviously cheap or clearly expensive. With the broader metrics pointing to an overall high value score, the current level raises the question of whether the recent gains still leave enough room for further upside. Clover Health Investments' 227.7% share price gain over 3 years sets a high bar...

Clover Health Investments, Corp. has already reported its second-quarter 2026 results, posting revenue of US$743.17 million versus US$477.62 million a year earlier and moving from a net loss of US$10.58 million to net income of US$28 million. Alongside this shift to profitability, the company highlighted strong Medicare Advantage membership growth and benefits from its AI-powered Clover Assistant platform, which management views as central to supporting future operational and financial...

Clover Health’s second quarter results were met with a positive market reaction, driven by strong Medicare Advantage membership growth and improved profitability. Management credited the quarter’s performance to the expansion of its Clover Assistant AI platform and disciplined focus on core markets, particularly New Jersey and Georgia. CEO Andrew Toy emphasized that “better clinical care leads to stronger cohort economics,” pointing to the impact of maturing member cohorts under the company’s te

Medicare Advantage membership surged 48% as profitability improved sharply.

Clover Health Investments (NASDAQ:CLOV) is positioning its Medicare Advantage model around earlier identification and treatment of chronic conditions, Interim Chief Financial Officer Clay Thornton said during a Canaccord Genuity conference presentation. Thornton said the company’s goal is to equip

Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many of these businesses are speculative and lack the underlying fundamentals to support their prices.

Moby summary of Clover Health Investments, Corp.'s Q2 2026 earnings call

Clover Health Investments Corp (CLOV) delivers robust Q2 2026 results with improved underwriting and expanding non-insurance businesses, driving a confident full-year outlook.

Clover Health Investments (NASDAQ:CLOV) reported second-quarter results that showed continued Medicare Advantage membership growth alongside profitability, while raising its full-year 2026 outlook across its key financial measures. Chief Executive Officer Andrew Toy said the company views its Clove

Health insurance company Clover Health (NASDAQ:CLOV) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 55.6% year on year to $743.2 million. The company’s full-year revenue guidance of $2.96 billion at the midpoint came in 1.7% above analysts’ estimates. Its GAAP profit of $0.05 per share was $0.02 above analysts’ consensus estimates.

After years of burning cash and testing investor patience, Clover Health just posted results that bulls have been waiting for. But with medical costs creeping up and the stock already priced for perfection, the real question is whether this milestone is a turning point or a trap.

Toy retains a $44.68 million direct stake after the non-discretionary sale triggered by RSU vesting. Remaining tranches vest quarterly through October 2028, signaling predictable future sell-to-cover activity.

Clover Health Investments said in a regulatory filing on Friday that it ‌detected unusual login activity on some of its ‌information systems on July 4 and later found a hacker had ​gained access to three employee accounts through social engineering. • The health insurer said the affected accounts belonged to non-managerial health plan employees who handled member visit ‌scheduling and broker-facing sales ⁠work. • These accounts could access some personal and protected health information, according to the ⁠company, but not corporate financial or claims systems.